Therapix Biosciences (Israel) Financial Diagnostics

TRPX -- Israel Stock  

null 33.70  0.70  2.12%

The current investor indifference towards the small price fluctuations of Therapix Biosciences has created some momentum for investors as it was traded today as low as 33.0 and as high as 34.4 per share. The company directors and management did not add any value to Therapix Biosciences investors in March. However, most investors can still diversify their portfolios with Therapix Biosciences to hedge your portfolio against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 0.0. The very small Stock volatility is a good signal to investors with longer term investment horizons. This diagnostics interface makes it easy to digest most current publicly released information about Therapix Biosciences as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Therapix Biosciences price relationship with some important fundamental indicators such as market cap and management efficiency. Also please take a look at World Market Map.

Therapix Biosciences Note

The company recorded loss per share of 0.04. Therapix Biosciences had not issued any dividends in recent years. The entity had a split on 2014-01-12. Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel. Therapix Biosciences operates under Biotechnology classification in Israel and traded on Tel Aviv Stock Exchange. It employs 9 people. To find out more about THERAPIX BIO contact Ascher Shmulewitz at 972 3 616 7055 or learn more at http://www.therapixbio.com.

Therapix Biosciences Alerts

Therapix Biosciences is not yet fully synchronised with the market data
Therapix Biosciences has high likelihood to experience some financial distress in the next 2 years
The company reported revenue of . Net Loss for the year was (7.66M).
THERAPIX BIO has accumulated about 7.51M in cash with (6.01M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04.

Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 44.76M.

Management Efficiency

Therapix Biosciences has return on total asset (ROA) of (37.65) % which means that it has lost $37.65 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (216.64) % meaning that it generated substantial loss on money invested by shareholders.

Therapix Biosciences Technical and Predictive Indicators

Did you try this?

Run Money Managers Now

   

Money Managers

Screen money managers from public funds and ETFs managed around the world
All  Next Launch Module
Also please take a look at World Market Map. Please also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Search macroaxis.com